Core Insights - Sharp Therapeutics Corp. reported its third quarter 2025 financial results, highlighting a significant increase in investment in research and development programs, particularly for Gaucher, Niemann Pick C, and Progranulin programs [2]. Financial Performance - The company experienced a 34% increase in R&D spending compared to the same quarter in 2024, indicating a strong commitment to advancing its clinical programs [2]. Development Plans - Sharp Therapeutics aims to enter Phase I clinical trials in 2026, marking a key milestone in its development strategy [2]. Company Overview - Sharp Therapeutics is focused on developing first-choice small-molecule therapeutics for genetic diseases, utilizing a discovery platform that combines high throughput screening technologies and computationally optimized compound libraries [2]. - The company's approach aims to restore activity in mutated proteins, potentially allowing for treatment of genetic disorders with conventional pill-based medicines [2].

PITTSBURGH, Pa. and TORONTO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Sharp Therapeutics Corp. ("Sharp" or the "Company") (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule therapeutics for genetic diseases, today announced that it will present preclinical data from its lead Phase 1 ready ‘901 program being developed to treat Gaucher disease and Glucocerebrosidase (GBA) Parkinson's disease at the World Orphan Drug Congress 2025. The meeting will take place from October 27 to 29, 2025, ...